316 results about "White blood cell number" patented technology

The invention relates to a method for the removal of leucocytes from blood which comprises bringing blood that comprises infected leucocytes into contact with an adsorbent carrier that has a greater affinity for infected, activated and/or defective leucocytes than for uninfected leucocytes especially cellulose acetate. The method can be used in the apheresis treatment of diseases caused by pathogenic organisms, for example, HIV, HCV or malaria. It is especially useful for treatment of HIV.

There is provided a method for classifying and counting leukocytes with abnormal DNA amount, which comprises: (1) a step of staining cells in a sample obtained from a hematological sample by treatment with a hemolytic agent to lyse erythrocytes, with a fluorescent dye which can make a difference in the fluorescence intensity at least among mature leukocytes, leukocytes with abnormal DNA amount and immature leukocytes; (2) a step of introducing the sample containing the stained cells into a flow cytometer to measure scattered light and fluorescence of the respective cells; (3) a step of classifying leukocytes and coincidence cells/platelet clumps utilizing a difference in the intensity of a scattered light peak and a difference in the scattered light width; (4) a step of classifying and counting mature leukocytes, leukocytes with abnormal DNA amount and immature leukocytes, utilizing a difference in the scattered light intensity and a difference in the fluorescence intensity of leukocytes classified in the step (3).

A method for enumerating white blood cells and nucleated red blood cells. The method comprises the steps of:

• • (b) providing a lysed sample of whole blood;
  • (b) introducing the lysed sample to a light-scattering multi-angle depolarizing flow cytometer;
  • (c) removing depolarizing interference, e.g., lipid droplets and other measured particles;
  • (d) differentiating nucleated red blood cells and noise from white blood cells in the absence of depolarizing interference;
  • (e) differentiating nucleated red blood cells from noise in the absence of depolarizing interference and white blood cells; and
  • (f) differentiating possible platelet clumps.

The invention relates to an integrated microfluidic chip for capture of cancer cells in whole blood. The integrated microfluidic chip for capture of cancer cells in whole blood comprises three inlets, an erythrocyte lysis unit, a leucocyte capture unit, a cancer cell capture unit and an outlet, wherein the three inlets, the erythrocyte lysis unit, the leucocyte capture unit, the cancer cell capture unit and the outlet are connected orderly. The leucocyte capture unit comprises a first diverter, a soft magnetic microcolumn array and permanent magnets. The first diverter is connected with the soft magnetic microcolumn array. The permanent magnets are arranged at two sides of the soft magnetic microcolumn array. The cancer cell capture unit comprises a second diverter and a capture microstructure array, wherein the second diverter and the capture microstructure array are connected orderly. Compared with the prior art, the integrated microfluidic chip for capture of cancer cells in whole blood has the advantages of high integration degree, simple operation, high cell capture efficiency, simple manufacture processes and the like.

The present invention relates to a blood bag system, a method for its manufacture, and a process for reducing pathogens and leucocytes in biological fluids in particular in therapeutic quantities of platelet concentrates (PC) contained in the blood bag system, using UV-light and agitation, wherein part of the plasma of the PC is optionally exchanged against a platelet additive solution.

The invention discloses a differential blood count reagent which comprises the following components: (1) a cyanine anion compound selected form compounds expressed by the formula I or formula II, (2) an anode surfactant expressed by the formula III, IV or V and (3) at least one nonionic surfactant. The invention also discloses a kit containing the differential blood count reagent and a method of the differential blood count. By utilizing the reagent, the kit and the method, five subclasses of leucocytes can be quickly identified within a very short time, four-classification count is at least carried out, and immaturate cells and abnormal cells can be distinguished.

The invention discloses a recombinant Ganoderma Lucidum immunomodulatory protein (rLZ-8) which has anti-tumor effect and is expressed by Pichia pastoris, and a pharmaceutical preparation thereof. The rLZ-8 has the effect of directly killing or damaging NB4 or K562 or HL-60 or S180 or H22 cells and not affecting normal cells; and the rLZ-8 can quickly and efficiently induce a plurality of tumor cells to apoptosize in vitro, can also effectively kill the tumor cells in a body of a mouse tumor model, has no obvious toxic side effect, and can keep or raise the level of leucocytes. In addition, the invention also provides an anti-tumor pharmaceutical preparation type taking the rLZ-8 as a core composition.

Substituted imidazolidine derivatives of the formula I,in which B, E, W, Y, R, R2, R3, R30, e and h have the meanings indicated in the claims. The compounds of the formula I are valuable pharmaceutical active compounds, which are suitable, for example, for the therapy of inflammatory disorders, for example of rheumatoid arthritis, or of allergic disorders. The compounds of the formula I are inhibitors of the adhesion and migration of leucocytes and/or antagonists of the adhesion receptor VLA-4 belonging to the integrins group. They are generally suitable for the therapy or prophylaxis of illnesses which are caused by an undesired extent of leucocyte adhesion and/or leucocyte migration or are associated therewith, or in which cell-cell or cell-matrix interactions which are based on interactions of VLA-4 receptors with their ligands play a part. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use, in particular as pharmaceutical active compounds, and pharmaceutical preparations which contain compounds of the formula I.

The invention relates to a circulating tumor cell separation micro-fluidic chip device and an application method thereof. The device comprises a micro-fluidic chip (1) and a chip fixture (2). The micro-fluidic chip (1) comprises a chip inlet (11), a single-screw chip (12), rare cell collection tubes (13, 14) and a leucocyte outlet (15). A single-screw channel starts from the chip inlet (11) at the center of a circular spiral channel, passes through a semicircular starting channel and enters a spiral micro-fluidic channel. The tail end contains three outlets: rare cells with different particle sizes are respectively collected; and the chip fixture (2) is automatically in butt joint with inlet and outlet of the micro-fluidic chip (1). In comparison with the prior art, the micro-fluidic chip device of the invention has the following beneficial effects: a treated sample can be automatically subjected to automated high-throughput tumor cell separation and tumor cells in a liquid sample such as peripheral blood/pleural effusion/cerebrospinal fluid, etc. of a cancer patient can be enriched; and cancer patient diagnosis and customized treatment specificity and accuracy are remarkably enhanced.

The invention relates to a hemolytic agent for a blood cell analysis device. The hemolytic agent is capable of cracking the erythrocytes in the blood, and the blood with cracked erythrocytes can be used for hemoglobin concentration determination. In addition, the invention also relates to a leukocyte classification reagent system which comprises the hemolytic agent and an inhibitor. After the hemolytic agent cracks the erythrocytes, the inhibitor can be added into the blood to prevent the hemolytic agent from damaging the morphology and structure of the leucocytes. Furthermore, the invention also relates to a method of classifying the leucocytes by using the reagent system.

The invention concerns a reagent for determination of leucocytes and measurement of haemoglobin in a sample of blood. This reagent comprises a buffer system that is suited to adjust selectively the pH of the reagent to an acidic value, at least one detergent of cationic type, a nitrogenous compound and, optionally, at least one inorganic salt. This reagent can be used in haematological analyses in human medicine and also permits the identification of a leucocytic subpopulation, in particular the basophil polymorphonuclear leucocytes.

Methods of treating tumors, reducing white blood cell numbers, and inhibiting CD promoters are provided.

the invention discloses a preparing method of extracellular polysaccharide of Bacillus subtilis and application in the tumour facet, which is characterized by the following: inhibiting tumour from growing; accelerating the growth of macrophage, leucocyte and lymph cell; fitting for health or immune adjusting drug.

The present invention is to present a blood analyzer which can prevent an abnormal number of white blood cells caused by the lipid particles or the red blood cells of poor hemolysis from being output. The blood analyzer comprises: first white blood cell number obtaining means; second white blood cell number obtaining means; output means for outputting the number of the white blood cells obtained by the second white blood cell number obtaining means, and determining means for determining whether the number of the white blood cells obtained by the second white blood cell number obtaining means is abnormal, wherein the output means is configured to output the number of the white blood cells obtained by the first white blood cell number obtaining means when the determining means determines that the number of the white blood cells obtained by the second white blood cell number obtaining means is abnormal.

The present invention relates to an leucocyte antigen mediated microfluidic assay and a microfluidic device for analyzing a subjects' body fluids containing leucocytes to determine if the subject has been previously exposed to a predetermined antigen.

The present invention relates to one kind of immune cell microfluid array belonging to the field of cell immunity test technology. On the polymer substrate of the immune cell microfluid array, there are orderly arranged pores communicated via inclined micro tubes. By using the present invention, once operation can detect cell with corresponding leucocyte differentiating antigen, and thus judges the kind of leucocyte differentiating antigen and the growth and decline rule of the leucocyte differentiating antigen. The present invention results in high working efficiency.

The invention discloses an electrocerebral non-linear dual-measure feature extraction and fusion processing method, and relates to the field of electrocerebral signals. The method comprises the following steps: acquiring an electrocerebral signal; performing data preprocessing on the electrocerebral signal; extracting an LZC (Leucocyte Zinc Content) complexity feature from preprocessed data; extracting a sample entropy feature, and performing feature analysis on the LZC complexity feature and the sample entropy feature; establishing a classification model with an SVM (Support Vector Machine) classifier by jointly taking the LZC value of the electrocerebral signal and a sample entropy value which are remarkably different as a feature parameter in order to classify and identify people in different psychological states. By adopting the method for classifying and identifying the electrocerebral signals of people in different psychological states, higher classifying accuracy can be achieved, and an objective evaluation index can be provided for the partition of people in different psychological states.

The invention provides an erythrocyte lysis buffer. The erythrocyte lysis buffer comprises the following components: 4.5-5.5 mmol/L of sodium chloride, 0.8-1.3% (v/v) of triton 100, 300-340mmol/L of glucose and 0.008-0.012 mol/L of trishydroxymethyl aminomethane. The erythrocyte lysis buffer can effectively lyse the erythrocyte in a whole blood sample, separate and enrich leucocyte in the blood, and facilitate the subsequent nucleic acid extraction operation of the leucocyte, so as to obtain the leucocyte DNA in the whole blood sample and the DNA of virus in the leucocyte.

The invention discloses a blood smear self-focusing microimaging method, which comprises an objective table for holding a blood smear, a focusing motor for driving the objective table to move, and a shooting device for shooting blood smear pictures in the moving process of the objective table. The method comprises the following steps: S1) the blood smear is prepared and placed on the objective table, wherein the objective table locates at a focusing start point; S2) the focusing motor drives the objective table to move to a focusing end point at a first preset speed; S3) in the moving process of the objective table in the step S2), the shooting device shoots the blood smear pictures with a preset frequency and records the shooting position; and S4) the obtained pictures are subjected to processing through a focusing evaluation function, and the position where a focal plane locates is obtained through the processed pictures to obtain clear imaging of leucocytes in the blood smear. The pictures shot by the shooting device are processed through the focusing evaluation function, and imaging of the blood smear is obtained according to the processed images, so that focusing can be realized without labor, and manpower and material resources are saved.

The invention discloses a hemolytic agent which contains at least one organic acid whose content ranges from 1 to 20g/L, and relates to a multipurpose hemolytic agent, which can be used for automatic hemanalysis, and can accurately test hematoglobin and keep the normal classification of leucocyte at the same time. A stabilizing agent of hematoglobin derivants is added in the hemolytic agent, thereby preventing the derivants from changing along with the reaction temperature change, and ensuring that an accurate and stable test result can be obtained within the normal service temperature range of the instrument.